Navigation Links
Distinguishing friend from foe in the battle against cancer

The latest generation of cancer chemotherapeutic drugs specifically targets mutant enzymes or "oncoproteins" that have run amok and now promote uncontrolled cell growth. As promising as these drugs are, cancer cells with their backs against the wall have the tendency to fight back. A major goal of cancer research is to frustrate these acts of cellular desperation.

In a forthcoming issue of Cancer Cell, investigators at the Salk Institute for Biological Studies uncover one means cancer cells use to stay alive and in doing so suggest a strategy to overcome their recalcitrance. The study, led by Tony Hunter, Ph.D., in collaboration with Inder Verma, Ph.D., shows that resistance to the chemotherapeutic drug rapamycin is mediated by the survival factor NF-kB.

Rapamycin, like the pharmaceutical superstar Gleevec, which revolutionized the treatment of chronic myelogenous leukemia, is a so-called signal transduction inhibitor or STI, a small molecule that stifles inappropriate growth signals sent by mutant proteins in cancer cells. STIs may look like overnight successes, but they are actually the result of decades of hard work.

"We have been working for 35 years looking at mechanisms underlying formation of cancer cells," says Hunter, an American Cancer Society professor in the Molecular and Cell Biology Laboratory. "We've made huge progress identifying specific events that change normal proteins into proteins that cause cancer and developing drugs that target those proteins. This work provides another potential direct target for development of cancer drugs."

The Hunter lab previously showed that mouse cells lacking tumor suppressors known as TSC genes are more susceptible to the lethal effects of chemotherapeutic agents than are normal cells. Why cells from these TSC null mice were so poorly equipped to survive was not entirely clear.

Co-lead authors Sourav Ghosh, Ph.D., and Vinay Tergaonkar, Ph.D., postdoctoral fellows in the respe
'"/>

Source:Salk Institute


Page: 1 2 3

Related biology news :

1. W.M. Keck Foundation funds study of friendly microbes
2. Plants respond similarly to signals from friends, enemies
3. Grass makes environmentally friendly biofuel
4. Plant pathologists evaluate eco-friendly alternatives to methyl bromide
5. FDA approves child-friendly AIDS medicine
6. Mans best friend: Study shows lonely seniors prefer playtime with pooch over human interaction
7. Eco-friendly bug sucker
8. Surprising symbiosis: Glassy-winged sharpshooter eats with friends
9. Train your brain to hear your friends at a party
10. Mans best friend lends insight into human evolution
11. UN environmental agency steps up battle against marine pollution
Post Your Comments:
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
(Date:12/2/2009)PHILADELPHIA Less acculturated Latino men have a more difficult time quitting smoking than those who are more acculturated to U.S. culture, but acculturation has no affect on Latinas odds of quitting
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2CCNY professor foresees rising Antarctic snowmelt 2Acculturation affects smoking cessation success among Latinos 2Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award 60266 1Blue Cross and Blue Shield of Floridas Power of the Human Voice Campaign Wins Prestigious DMA International ECHO Gold Award 60266 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 1NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 3NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 4NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 5NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 6NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 7NIEHS awards Recovery Act funds to address bisphenol A research gaps 10565 8New Clues to How Fish Oils Help Arthritis Patients 60263 1New Clues to How Fish Oils Help Arthritis Patients 60263 2
...wheat stem sawfly natural enemies in demand, Monta...g ways of increasing their availability. , This ...study that involved mass-rearing parasitic wasps t...e interior of developing wheat plants. The team in...te Godshen Pallipparambil-Robert and undergraduate...
...niversity of Cincinnati (UC) has received $2.4 mil...stimulate the body,s natural defense system to cau...iseases. , Michael Borchers, PhD, believes long-t...y activate a specific receptor--known as NKG2D--in...k stressed (damaged) lung tissue. , "When tissue...
...iscovery of a DNA marker for two key rust resistan...ld to breed more effective rust resistant wheat va...d together and provide wheat plants with improved ...major diseases of wheat in Australia and worldwide...agudah, says various types of rust resistance have...
Other Biology News:Rearing an army to save wheat 2Rearing an army to save wheat 3Environmental toxins may cause body's defenses to worsen lung disease 2Environmental toxins may cause body's defenses to worsen lung disease 3Elusive rust resistance genes located 2
(Date:12/3/2009)MELVILLE, N.Y., Dec. 3 Nikon Corporation, an innovator of advanced optical instruments, announced today that it has signed a licensing agreement with Harvard University granting Nikon the rights to u
(Date:12/3/2009)SAN FRANCISCO, Dec. 3 VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today anno
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/3/2009)HOPKINTON, Mass., Dec. 3 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today introduced Living Image 4.0 softwa
Breaking Biology Technology:Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 2Nikon Corporation Acquires License From Harvard University For 'STORM' Super Resolution Microscopy -- Will Create Innovative New 'N-STORM' Microscope 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Caliper Life Sciences Launches Living Image(R) 4.0 Software 2
...all/ - YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ...velops and commercializes differentiated products ... completed accrual in the first 50-patient,cohort ...n with irinotecan,for the treatment of colorectal ... consistent with data from previous trials of nimo...
...eutics, Inc.,a biopharmaceutical company developin... announced the appointment of Colin Reisner, MD, F...r and Executive Vice,President of Clinical Develop...e position of Vice President, Regulatory Affairs a...nd Michael as we continue to build,our team with e...
..., a privately,held orthobiologic company, announce...e Finance Forum in San Francisco, CA from January ... CEO of ISTO, will present on,Tuesday, January 8th...ake,Hotel at 450 Powell St. Information about the ...www.onemedplace.com ., ISTO,s rich product pipeli...
Other Biology Technology:YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 3Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 2Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 3
...oduced by a patented microwave process which makes..., even cell attachment, increased cell growth and ...th uunder difficult conditions, including reduced ...ovide a more ecominic alternative to expensive and...
...es are designed for quick and easy protein purific...re two 0.25mm holes laser cut at the conical ends ... incubation of the gel matrix with buffer, during ...the buffer. Following a centrifugation step, the p...
...-art in permanent mounting media. It is designed f...al organic insoluble substrates such as diaminoben... organic solvent compatible chromogen substrates o...y and cytology applications using manual and autom...
...ndustry's first siRNA sequence design software in ...ls consistent with new experimental strategies and... With the introduction of our new, enhanced, and e...to offer the most significant advancement in RNAi ...
Biology Products: